RIVIVE

Growth

naloxone hydrochloride

NDANASALSPRAY, METEREDPriority Review
Approved
Jul 2023
Lifecycle
Growth
Competitive Pressure
0/100

Loss of Exclusivity

LOE Date
May 11, 2032
75 months away
Patent Expiry
May 11, 2032

Patent Records (3)

Patent #ExpiryTypeUse Code
11020343
May 11, 2032
U-3671
11806428
May 11, 2032
Product
—
12458591
May 11, 2032
U-3671
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers